The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: The case of lamotrigine

Disease Management

Volumn 10, Issue 4, 2007, Pages 216-225

  Mei, Sheng Duh ^a   Andermann, Frederick ^b   Paradis, Pierre Emmanuel ^c   Weiner, Jennifer ^a   Manjunath, Ranjani ^d   Cremieux, Pierre Yves ^a  

^a ANALYSIS GROUP   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c GROUPE D ANALYSE   (Canada)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG; LAMOTRIGINE;

ARTICLE; BILLING AND CLAIMS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG SUBSTITUTION; HEALTH CARE UTILIZATION; HOSPITAL INFORMATION SYSTEM; MANDATORY PROGRAM; PHARMACY;

ADULT; ANTICONVULSANTS; COST SAVINGS; DRUG COSTS; DRUG UTILIZATION; DRUGS, GENERIC; EPILEPSY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; PRESCRIPTIONS, DRUG; PROSPECTIVE PAYMENT SYSTEM; QUEBEC; RETROSPECTIVE STUDIES; TRIAZINES;

EID: 34548647524     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2007.104649     Document Type: Article

References (21)

1. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003;25:1578-1592.
2. Health Canada. Report C of the Expert Advisory Committee on Bioavailability. Available at: 〈http:// www.hc-sc.gc.ca/dhp-mps/prodpharma/ applicdemande/guide-ld/bio/biorepc_biorapc_e.html〉. Accessed June 19, 2007.
3. Ministry of Health and Long-Term Care. Ontario Guidelines for Drug Submission and Evaluation, September 2000. Available at: 〈http://www. health.gov. on.ca/english/providers/pub/drugs/dsguide/docs /dse_guide.pdf〉. Accessed June 19, 2007.
4. st Annual North American Regional Epilepsy Congress; December 3, 2006; San Diego, CA.
5. Andermann F, Duh MS, Gosselin A, Lefebvre P, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to brand compounds compared to other drug classes. Epilepsia. 2007;48; 464-469.
6. Hellstrom J, Rudholm N. Side effects of generic competition? Eur J Health Econ. 2004;5:203-208.
7. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs. Available at: 〈http://www.fda.gov/cder/ogd/ 〉. Accessed June 19, 2007.
8. Tyrer JH, Eadie MJ, Sutherland JM, Hooper WD. Outbreak of anticonvulsant intoxication in an Australian city. BMJ. 1970;4:271-273.
9. MacDonald JT. Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology. 1987;37:1885.
10. Wyllie E, Pippenger CE, Rothner AD. Increased seizure frequency with generic primidone. JAMA. 1987;258:1216-1217.
11. Gilman JT, Alvarez LA, Duchowny M. Carbamazepine toxicity resulting from generic substitution. Neurology. 1993;(43):2696-2697.
12. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav. 2004;5:995-998.
13. Crawford P, Hall WW, Chappell B, Collings J, Stewart A. Generic prescribing for epilepsy. Is it safe? Seizure. 1996;(5):1-5.
14. American Academy of Neurology. Assessment: generic substitution for antiepileptic medication. Neurology. 1990;40:1641-1643.
15. Feely M, Crawford P, Krämer G, Guberman A. Risk management in epilepsy: generic substitution and continuity of supply. The European Journal of Hospital Pharmacy Science. 2005;11:83-87.
16. Sander JW. The use of antiepileptic drugs: principles and practice. Epilepsia. 2004;45(suppl 6):28-34.
17. Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs. 2004;18:617-628.
18. Berkovic SF. Treatment with anti-epileptic drugs. Aust Fam Physician. 2005;34:1017-1020.
19. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med. 2005;142:891-897.
20. Crawford P, Feely M, Guberman A, Kramer G. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure. 2006;15:165-176.
21. Ontario Drug Benefit Formulary/Comparative Drug Index, No. 39. Available at: 〈http://www.health. gov.on.ca/english/providers/program/drugs/ formulary/ed39_0_bk.pdf〉. Accessed June 19, 2007.